The US Food and Drug Administration (FDA) has granted fast track designation to ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) for the treatment of non-small cell lung cancer (NSCLC).

The FDA issued another complete response letter for odronextamab for the treatment of relapsed/refractory follicular lymphoma.

Black men with newly diagnosed prostate cancer have lower odds of overtreatment and confirmatory testing when compared to their White counterparts, data suggest.

Resection beyond contrast-enhancing tumor margins is associated with superior outcomes in patients with primary glioblastoma, a study suggests.